The presence of lecithin:cholesterol acyltransferase (LCAT) deficiency in six probands from five families originating from four different countries was confirmed by the absence or near absence of LCAT activity. Also, other invariate symptoms of LCAT deficiency, a significant increase of unesterified cholesterol in plasma lipoproteins and the reduction of plasma HDLcholesterol to levels below one-tenth of normal, were present in all probands. In the probands from two families, no mass was detectable, while in others reduced amounts of LCAT mass indicated the presence of a functionally inactive protein. Sequence analysis identified homozygous missense or nonsense mutations in four probands. Two probands from one family both were found to be compound heterozygotes for a missense mutation and for a single base insertion causing a reading frame-shift. Subsequent family analyses were carried out using mutagenic primers for carrier identification. LCAT activity and LCAT mass in 23 genotypic heterozygotes were approximately half normal and clearly distinct from those of 20 unaffected family members. In the homozygous patients no obvious relationship between residual LCAT activity and the clinical phenotype was seen. The observation that the molecular defects in LCAT deficiency are dispersed in different regions of the enzyme suggests the existence of several functionally important structural domains in this enzyme. (J. Clin. Invest. 1993. 
of LCAT activity in plasma (1) . LCAT is synthesized in the liver and released into the plasma (2) where it functions in the transfer of the sn-2 fatty acid of phosphatidylcholine to the 3-OH group of cholesterol. Cholesterol esters that are formed in this enzymatic reaction are subsequently transferred into the hydrophobic core of plasma lipoproteins, preferentially into HDL (3) . The LCAT reaction participates in a process of reverse cholesterol transport whereby excess cellular cholesterol is transferred to the liver from where it can leave the body by bile acid formation or direct secretion into the bile. In LCAT deficiency, the composition, shape, and concentration of all plasma lipoproteins is abnormal. Mature HDL, whose formation crucially depends on the LCAT reaction, are absent from the plasma of affected patients. In addition, erythrocyte membranes of affected patients contain abnormally high amounts of unesterified cholesterol and phosphatidylcholine (1) .
Clinically, familial LCAT deficiency frequently presents with corneal opacities, normochromic anemia, and proteinuria. Foam cells are present in bone marrow and glomeruli and focal and segmental glomerulosclerosis may develop. Progressive renal failure is a common complication in the fourth and fifth decade oflife. Furthermore, premature atherosclerosis has been observed in some patients with familial LCAT deficiency (1, 4) .
Currently, about 30 cases of homozygous familial LCAT deficiency have been reported from 11 countries in Europe and North America, and from India and Japan. However, there are no reliable figures on the prevalence of this disease. For a secluded area in Norway, however, the heterozygote frequency has been estimated to be as high as 4% (1) .
Previously, we have reported that the basic defect in fish eye disease, a disorder in which LCAT selectively does not esterify cholesterol contained in small size lipoprotein particles, is caused by a missense mutation resulting in a substitution of isoleucine for threonine at residue 123 of the LCAT protein (5) . Recently, two other mutations in families with fish eye disease (6, 7) and five different mutations in classical familial LCAT deficiency have been reported (8-1 1 ).
In this report we characterize the molecular basis of LCAT deficiency in five families from four different countries (France, Denmark, Canada, and Italy [two cases]). We show six new mutations in these patients. Familial Table I are from this visit. The 38-yr old male Italian patient in family E presented with corneal opacifications, proteinuria (3 g/d), and normochromic anemia (red blood cells 3.79 X 10 2/liter) with increased numbers oftarget cells. Urea nitrogen, plasma creatinine, and endogenous creatinine clearance were normal. A renal biopsy showed interstitial and glomerular accumulation of lipids. The family ofthis patient was not available for analysis.
Determination of LCAT mass and activity. Blood and EDTAblood were collected from all probands after an overnight fast. Plasma lipid and lipoprotein concentrations were determined by standard procedures (16) . LCAT activity was determined using exogenous (17) and endogenous (18) substrates. In the exogenous assay an artificial substrate particle composed of egg yolk lecithin, unesterified cholesterol, and apolipoprotein A-I is used, while in the endogenous assay radiolabeled cholesterol is added to plasma at 4°C and the resulting esterification is measured after incubation at 37°C. Results from this latter assay are termed cholesterol esterification rate (CER). LCAT mass was determined by radioimmunoassay using polyclonal antibodies as previously described (19) . Phenotype assignment was based on LCAT activity measured with the use of exogenous substrate. 20 nmol/ ml per h, which is > 2 SD below the mean for normals (17) , was used as the cutoff between normals and heterozygotes; all probands had LCAT activities below 2 nmol/ml per h. Sequence analysis. The LCAT genes of the homozygous patients were sequenced directly from single stranded DNA templates prepared by two rounds of PCR amplification (20) following a previously described protocol (5) . No prolonged initial denaturation step was used; the extension time ofthe last cycle was 7 min. The resulting 43 1-bp PCR product was purified by agarose gel electrophoresis (3% NuSieve, 0.5% SeaPlaque, FMC Corp., Rockland, ME) at 10 V/cm and subsequent electroelution. Desalting and concentration was done as described (21) . Single strand production was done using 0.001 parts of the purified product from the double strand PCR reaction as template. Concentrations of the upper and lower strand primers were 10 nM and 300 nM, respectively. 45 amplification cycles and no final extension were used in an otherwise unchanged protocol. The purified product was dried in a vacuum centrifuge. Sequence analysis was done with the fluorescence-labeled M 13 primer of the AutoRead sequencing kit (Pharmacia) and all ofthe reaction product from the asymmetric PCR as template following the protocol ofthe kit supplier.
Genotype determinations. Genotypes were determined with the use of mutagenic PCR primers, a method described in principle by Kumar and Barbacid (22) and Kumar and Dunn (23) . We have previously used this method in the determination ofcarriers ofthe fish eye disease (FED) mutation (5) . Primer synthesis and purification were done as described (21) .
Results
The presence of LCAT deficiency in the five investigated families was verified by the absence or near absence of LCAT activity from the plasma of the probands. Other hallmarks of this disease, an increased cholesterol to cholesterol ester ratio in plasma and the almost complete absence of HDL cholesterol, were also seen in all six patients. In addition, LCAT mass was absent or severely reduced in all probands. Also, several first degree relatives of the probands showed marked changes in these parameters. The clinical symptoms of the probands are summarized in Table I ; biochemical parameters are listed in Table II .
The genetic nature of the disease was ascertained by the identification of several individuals in each family with LCAT activities below 20 nmol/ml per h, an activity that is 2 SD below normal (17) . Additional data on the heterozygote as well as the normal relatives from the affected families are shown in Table II . Clinical abnormalities in heterozygotes were not seen. Of note are the marked reductions in HDL cholesterol and apo A-I concentrations in the heterozygotes of kindreds A, B, and C compared to the unaffected family members.
Sequence analysis ofthe LCAT genes ofthe probands in all cases showed deviations from the wild type sequence reported by McLean and co-workers (2). In four ofthe five families the patients were homozygous for their genetic defect. The two probands in the Canadian family (family C) were compound heterozygotes with one missense mutation and a frameshift mutation due to a single base insertion. Four of the six defective alleles identified in the five families carried missense muta- The table shows the nucleotide sequences of the mutagenic PCR primers used in the detection of the indicated mutations. The corresponding primers were placed 287 bp to 439 bp downstream or upstream of these primers. The sequence modifications of the mutagenic primers are printed in italic. The parts of the restriction enzyme recognition sites that are located within the primers are underlined. PCR product fragment lengths resulting after digestion with the appropriate endonuclease of the wild type or mutant allele are indicated. Information on the mutated codons is given as upper strand sequence irrespective of the orientation of the mutagenic primer. The base insertion between codons 375 and 376 was diagnosed by sequencing.
The likelihood for a causal relationship between the observed mutations and the LCAT deficient phenotype was assessed by segregation analysis. Fig. 2 gives an example of this type of analysis, where phenotype assignments were based on plasma LCAT activity and genotypes were assessed by the presence of selectively introduced restriction enzyme cutting sites. No deviations between genotype and phenotype were observed in families A, B, and C. In families D and E only probands were analyzed.
To exclude further the possibility that the identified sequence variations merely represent frequent polymorphisms rather than functionally important mutants we checked the DNA of 150 students from Mflnster University. None of the reported mutations were seen in any of these DNA samples. Moreover, complete sequence analysis of the LCAT genes from five apparently healthy individuals and of one heterozygote carrier for each of the defective alleles did not yield any difference from the wild type sequence.
Discussion
We have identified six different mutations in the LCAT gene in five patients with familial LCAT deficiency. The familial nature of the disease in these patients was determined by extensive pedigree analyses (families A-C) and the previously published findings on family D ( 15) . Low HDL cholesterol levels seen in several first degree relatives of the proband in family E is indicative for the familial nature of the disease also in this family.
In three families we have performed segregation analysis to assess the relationship of genotype with phenotype. In the plasma of genotypically homozygous (or compound heterozygous) patients, none or only minute residual LCAT activity was found, while all genotypic heterozygotes showed a reduction in their LCAT activity to 50-60% of normal. Sequence analysis ofall exons, the splice donor and acceptor sites, and of the 5' consensus regulatory elements yielded only the reported mutations. It thus appears likely that the identified mutations are causative for the observed phenotypes. The possibility that these mutations represent functionally unimportant changes in DNA sequence is unlikely. Such a hypothesis requires the existence of a neighboring gene that interferes with LCAT activity that would have to be in linkage disequilibrium with several allelic mutations in the LCAT gene which are otherwise not found in the population. Moreover familial LCAT deficiency. Taken together, there is strong evidence that the mutations we have identified in the LCAT gene are causative for familial LCAT deficiency.
As it is expected for a rare recessive trait, most of the patients carry two identical defective alleles. An exception in this regard is the Canadian family where the two clinically affected patients are compound heterozygotes for two different mutations. This probably reflects the different paternal and maternal ancestral origins for these patients. Since neither LCAT mass nor LCAT activity was detectable in the two affected persons in this family the missense mutation in codon 135 and the frameshift mutation appear to be functionally equivalent. This is further supported by the absence of differences in the biochemical phenotype between heterozygote carriers of the two mutations.
A recent report on phenylalanine hydroxylase deficiency showed that different defects in this enzyme were predictive of different levels of enzyme activity and of the severity of the disease (24) . Similarly, two different mutations in the arylsulfatase A gene have been found to provide a structural basis for early and late onset of metachromatic leukodystrophy (25) . It is thus interesting to know if also in LCAT deficiency different mutations in the enzyme gene are responsible for the variation ofclinical symptoms. In the cases reported here, some variability was observed in the age of onset of symptoms and in the severity of clinical complications. As none of the families shared identical mutations, it remains unknown at present if this heterogeneity is genetically determined. The residual level of plasma LCAT activity, however, does not appear to be predictive for associated clinical symptoms, as the clinical symptoms in the patients reported in this paper show a considerable variance despite the absence or near absence of LCAT activity in all cases. Also, the two affected patients in family C, who have identical LCAT defects, show a considerable variability in their clinical phenotypes ( 12) . It may therefore be speculated that the expressivity of the clinical disease is modulated by the absence or presence of additional effects of the environment and of minor genes.
There have been previously reported defects in the LCAT gene. These include missense mutations in codons 147, 228, and 293 (references 8-10), a single nucleotide insertion in exon 1 ( 11) , and an in frame GGC (Arg) insertion between codons 140 and 141 (9) , all found in patients with classical familial LCAT deficiency, and missense mutations in codons 10, 123, and 347 (5-7) causing familial partial LCAT deficiency in a disorder termed FED. Including the mutations reported in this paper, 13 different mutant alleles of the LCAT gene are known currently which all are associated with marked impairments of LCAT function. In most cases the loss of LCAT activity is associated with the absence of LCAT mass from the plasma compartment. Exceptions are the mutations in codons 147, 228, and 293, where no or very little LCAT activity but 40-60% of normal mass was found, and the FED defects, in which the ability of LCAT to act on small substrate particles is lost despite the presence ofhalfnormal LCAT mass. Other examples of LCAT deficiency, for which the basic defects are as yet unknown, show a reduction in LCAT mass to 20-40% and in LCAT activity to 0.1-13% ( 1 ) . Based on these observations the existence of different mutations causing LCAT deficiency had been proposed. Recent reports and our current data confirm this hypothesis and, moreover, suggest that LCAT activity may be reduced by one or more of several different mechanisms. From the observations made in FED it has been hypothesized that LCAT may in fact have at least two functionally important domains one of which is the catalytic center and the other a recognition site for small size substrate particles. The identification ofmutations in different regions of the LCAT gene that cause familial LCAT deficiency is in support ofthe presence of several different domains important for LCAT function.
Based on clinical as well as on biochemical differences we can currently define two classes of familial LCAT deficiency: an a-type and an a,#-type. The terminology reflects the inability ofdifferent mutant LCAT enzymes to interact with a-and/ or E-migrating lipoproteins in vitro. Surprisingly, the currently known mutations in the a-type of LCAT deficiency are not confined to a specific region of the protein. If this relates to complex secondary or tertiary structure requirements for substrate specificity ofthe enzyme or ifit simply reflects the unproven genotype with phenotype relation in two of the defects (6, 7) is currently not known. The a-entity of LCAT deficiency is clearly distinct from LCAT deficiencies of the a,f3-type by a normal cholesterol esterification rate and the absence ofhematological and nephrological symptoms even at high age. All other LCAT deficiencies with known basic defects are of the a,3-type. As mentioned above variance in the clinical expression of a,#-type LCAT deficiencies is more likely caused by a different genetic and environmental background than by their different basic mutations. Also, it is of interest to note that, different from a previous report (1), the LCAT-deficient patients reported here have no apparent signs of congenital heart disease.
Although a number ofeasily definable biochemical parameters, like HDL cholesterol or free cholesterol:total cholesterol ratio, are significantly altered in familial LCAT deficiency these findings do not show the consistency required of a diagnostic marker. Therefore, the diagnosis of LCAT deficiency should be based on the absence or near absence ofLCAT activity measured with exogenous substrates. A distinction between severe forms (a,13-type LCAT deficiency) and mild forms of the a-type can be made by the measurement of LCAT activity using endogenous substrates. Secondary forms of LCAT deficiency which occur in conjunction with primary HDL deficiency usually show half normal LCAT activity (21, 26, 27) . In most cases this condition can be distinguished from heterozygous primary LCAT deficiency by the pattern ofinheritance, as most heterozygotes for primary HDL deficiency have near normal LCAT activity.
